Warning: Creating default object from empty value in /home/cmklara/ftp/domains/en.terapiekomorkowe.pl/public_html/wp-content/themes/singlepro_v2.2/inc/Framework/ReduxCore/inc/class.redux_filesystem.php on line 29
Neurology – Center for Cell Therapy and Immunotherapy


The goal, principle and scheme of the medical therapeutic experiment:

A medical therapeutic experiment is a multi-stage procedure aimed at applying an innovative method of treatment, technology or an innovative therapeutic preparation, which is not a standard therapy for a given illness. The medical therapeutic experiment is an alternative for patients who have not yet been treated or previous treatment has not produced the desired therapeutic effects. The main goal of the medical therapeutic experiment is to improve the patient’s health. The use of MSC therapy as part of a medical therapeutic experiment must always be supported by the consent of the Bioethical Commission at the District Medical Chamber in Częstochowa, Poland.

What are stem cells obtained from Wharton jelly?

Wharton’s jelly-derived mesenchymal stem cells – WJ-MSC are a population of multipotent stem cells, located in the umbilical cord, classified as gelatinous connective tissue.
Wharton jelly is made up mainly of mucopolysaccharides, including hyaluronic acid and chondroitin sulphate.
The mesenchymal stem cells used in the experiment have a fibroblast structure, show adhesion to plastic substrates and originate from unrelated and incompatible in the antigen range of tissue compliance and the main groups and Rh blood factor, donor.

Title of the medical therapeutic experiment:

“The use of mesenchymal cells obtained from a Wharton jelly incompatible donor unrelated to the treatment of patients with neurological diseases in which there is no causative treatment and in which the treatment did not bring any improvement in the clinical condition.”

Who can take part in a medical therapeutic experiment in the field of neurology?

  • Multiple Sclerosis (MS)

Central nervous system disease of a chronic and inflammatory nature. In its process, multifocal nerve tissue damage occurs. The disease causes the destruction of the myelin sheath around the protrusions of nerve cells, as a result of which the proper transmission of impulses along the nerve pathways in the brain and spinal cord is disturbed.

  • Amyotrophic lateral sclerosis (ALS)

A disease that causes damage to the central and / or peripheral nervous system, resulting in the loss of the hand muscles, paresis of the lower limbs and a gradual loss of movement. The causes of ALS can be: various immunological diseases, free oxygen radicals, toxins and past viral infections. It is often a genetic disorder, followed by the following mutations: SOD1, ALSIN, VABP and SETX, and gene polymorphisms on chromosomes 9 and 19.

  • Muscular dystrophies

Hereditary degenerative diseases of muscle tissue, manifested by pathological changes in the muscle fibers and connective tissue. The change consists in the disappearance or improper construction of proteins – dystrophin and utrofiny, which function is to attach myofibril to sarcolemma.

  • Ataxia

A set of symptoms related to movement coordination of the body. The essence of the disease is incorrect synchronization and regulation of muscle tone, cooperating muscles of agonists and antagonists. Symptoms of ataxia may include gait abnormalities, clumsiness of upper limb movements as well as problems with rapid alternating movements. Ataxia may be the result of:
damage to the cerebellum, damage to the connections between the cerebellum and the core, subcortical and cortical centers, damage to the frontal lobes, damage to the back cord of the spinal cord.

  • Spinal muscular atrophy

A rare neuromuscular disease, manifested by the degeneration of the anterior spinal cord nuclei, and the result of progressive skeletal muscle impairment. In severe cases it can lead to early death. The disease is associated with a mutation within the SMN1 gene.

  • Cerebral palsy

A set of symptoms related to various movement disorders and attitudes that result from permanent, non-progressive brain damage in the early stages of development of the child. Problems are evident in motor coordination, varying degrees of stiffness or flaccidity of the muscles, swallowing of food and speaking. Occasionally, patients may experience seizures and problems with your eyesight and hearing. Symptoms of the disease intensify with the aging of the body.

  • Developmental disorders

Developmental disorder related to the reduction of the overall level of intellectual functioning, which is accompanied by problems in the field of adaptive behavior (mainly independence and responsibility).

  • Autism

Complex disorder of development and functioning of the central nervous system, mainly of a genetic basis. The most common symptoms are: difficulties in social relations, communication, limiting the imagination and impoverishment and stereotypical behavior.

  • Epilepsy

Epilepsy is one of the types of neurological disorders caused by temporary brain disability, which is manifested by unexpected discharges inside nerve cells. The diagnosis of epilepsy is the attacks of strong shocks associated with the loss of consciousness.

  • Meningocele

Congenital abnormalities caused by improper development of the nervous system at an early stage of fetal life (up to day 28 from conception). Part of the spinal cord and nerves coming from the spinal cord are located outside the spinal canal, which is visible in the form of a tumor on the back of the child.

  • Devic’s disease

A rare disease in which your own immune system attacks the spinal cord and optic nerves. The result is demyelination of the spinal cord and optic nerves. The disease affects muscle weakness, may cause paralysis of the legs and / or hands, loss of sensation, eye problems and bladder and bowel dysfunction.

  • Spinal cord cavity

A chronic, very rare disorder of the spinal cord.. It is characterized by the formation of tubular cavities in the spinal cord, usually in the cervical section, with a tendency to spread to the remaining sections. The main symptoms are: sensory disturbances, weakness, upper limb asymmetries combined with muscle wasting, as well as gait and sphincter disorders.

  • Moya-moya disease

A rare disease of unknown cause, usually found in the population of young Asians. It causes obstruction of large intracranial arteries, which in turn lead to ischemia of the central nervous system, manifesting itself in the form of receding ischemic attacks, strokes or cerebral haemorrhage.

  • Encephalopathy

Disease resulting from brain damage caused by factors of various origins. The reasons may be toxins formed in the body when liver or kidney failure, poisons, ie heavy metals, ethyl alcohol, etc. There are also infectious encephalopathies.

  • A cerebellar syndrome

The disease syndrome resulting from the damage of the trunk, and in particular the reticular formation above the red nuclei. It is manifested by serious disturbances of consciousness and very strong tension of limb extensor muscles. There are, however, cases when there is a bending position of the upper limbs. Symptoms of stiffness in an unconscious patient are often paroxysmal and are a reaction to tactile and pain stimuli. The non-brain stiffness is accompanied by severe trunk injuries, cerebral and subarachnoid haemorrhage, and sometimes with the occurrence of tumors and inflammations of the brain.

  • Delay in psychomotor development

Delay in the development of motor and mental functions of the child, which may indicate nervous system diseases. The reason may be:

  • congenital diseases of the nervous system, e.g. metabolic disorders, nervous system defects,
  • mother’s disease during pregnancy (eg rubella, toxoplasmosis, cytomegaly, etc.),hypoxia during delivery,
  • severe diseases in the first months of life (eg very severe jaundice, meningitis).
  • Ischemic stroke

Partial or total disruption of the brain, resulting from its ischemia and lasting more than a day.

Patients with more than one illness are also subject to experimental therapy.

General criteria for the selection of patients receiving therapy using WJ-MSC (Wharton’s jelly mesenchymal stem cells – Wharton jelly stem cells).

  • patients of both sexes,
  • age: from 3 to 85,
  • the obligation to use contraception during the course of therapy (applies to women).

Exclusion criteria from therapy:

  • pregnancy and breast-feeding,
  • severe or acute organ damage,
  • an infectious disease, e.g. HIV, HBV, HCV, HPV,
  • active infection requiring treatment,
  • severe mental disorders,
  • presence of malignant tumor,
  • unstable state of the cardiovascular system,
  • allergy to some antibiotics.

How can you qualify for MSC Therapy?

Patients are asked to send the following documents:

  • hospital treatment information with confirmation of diagnosis,
  • Laboratory results: quality HCV RNA, borrelia IGG and IGM by western-blot, anti HBs, HIV,
  • Hepatitis B vaccination record

to the following address: komorki@cm-klara.pl or by post: Centrum Medyczne Klara, MSC Therapy, ul. Wał Dwernickiego 43/45, 42-202 Częstochowa, Poland where initial verification will take place.

After doctor qualification for MSC Therapy, Klara Medical Center acts on behalf of the Patient for the Bioethical Commission at the District Medical Chamber in Częstochowa, Poland.

At this stage, patients wait for the application to be reviewed by the Bioethical Commission.

In the case of a positively examined application, Klara Medical Center contacts the patient in order to provide information on:

  • application dates
  • the cost of therapy
  • additional tests required
  • organizational information

Diagram of a medical treatment experiment:

As part of the approval of the Bioethical Commission, the patient can receive up to 10 administrations of MSC. The duration of therapy is about 1.5 years.

  • The interval between single administrations is 4-6 weeks – assessment of the treatment effect before each single injection.
  • After the fifth administration of MSC, the patient starts a 6-month break, unless there are medical grounds for continuing therapy without taking into account the interruption.
  • After the end of the 6-month interval, the therapy is resumed for a further 1-5 applications at intervals of 4-6 weeks or once every three months, if the patient’s condition has improved – assessment of the treatment effect before each single injection.

Frequently Asked Questions:

How long is the hospitalization at Klara Medical Center?
The patient spends 3 days in the hospital.
Day 1 – admission to the ward
Day 2 – administration of the MSC preparation
Day 3 – hospital discharge in the morning hours

Can a parent / guardian or family member stay with the patient while in the hospital?

Yes, the cost in included.

If you would like to receive more information about stem cells treatment, please contact us at:

komorki@cm-klara.pl and / or +48 34 534 5003